Refine by
Breast Cancer Articles & Analysis
280 news found
Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and ...
The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. ...
ByTempus
This month, from Frankfurt to Finland via Montigny-le-Bretonneux, Bertin Technologies Group employees around the world took part in “Pink October”, a month dedicated to prevention, information and fundraising in the fight against breast cancer. In addition to raising awareness of this disease by wearing a touch of pink, our colleagues in Basingstoke ...
” Now hospitals can use the technology while we learn more about the long term (>10 years) outcomes of using the NanoKnife System for prostate cancer as they collect their audit data. When men are diagnosed with prostate cancer it is graded as Low, Intermediate or High risk. ...
Tamoxifen Citrate Tamoxifen Citrate is a medication used to treat breast cancer and prevent its recurrence. It works by blocking the effects of estrogen on breast tissue, which can promote the growth of cancer cells. ...
“Advanced or metastatic ER+, HER2- breast cancer pre-treated with endocrine-based therapy remains an area of unmet medical need. ...
SMILE STUDY is a multi-institutional phase II clinical trial to determine the efficacy of an antiprogestin, Onapristone +fulvestrantas second line therapy for patients with HR+/HER2- metastatic breast cancer (MBC). Hypothesis: The proposed combination of therapy with onapristone + fulvestrant is effective for patients with metastatic ER+, and or, PR+/-, HER-2 ...
Dirbas in 2002 was an early adopter of accelerated, partial breast irradiation for surgical patients with early-stage breast cancer and served as Primary Investigator (PI) on Stanford’s successful investigator initiated APBI trial: he has also served as site-PI for other cooperative group trials related to breast ...
“Breast cancer is the most common cancer worldwide, impacting millions of women and their loved ones around the world,” said Dr. ...
ByBayer AG
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. Representative data of the liquid biopsy workflow will be presented at the American Association for Cancer Research (AACR) Annual Meeting ...
After 3 years of work, we announce the start of our clinical trials and the inclusion of a first patient eligible for breast reconstruction with #MATTISSE for her breast cancer. This is a world first for this type of technology, #madeinfrance totally resorbable, 3D printed, allowing a natural breast reconstruction, with a simple ...
“Menarini will continue to pursue research collaborations that have the potential to improve patients’ lives in breast cancer.” Carrick anticipates initiating the Phase 2 clinical trial in 2023. ...
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor ...
While DNA is largely identical in all cells, RNA fluctuates considerably both in presence and relative concentrations. The variation reflects the underlying cause of a cell’s character and thus RNA analysis gives a more accurate view of the state cells are in compared to DNA analysis. Gene expression levels are important to analyse, and quantitative RNA sequencing is the most informative ...
” Headquartered in Cardiff, Wales, and backed by a team of scientists, engineers, and manufacturing technicians, Cellesce technology produces uniform, human-derived cell or organoid lines including off-the-shelf colorectal cancer, gastrointestinal, and breast cancer organoids — with pancreatic and lung organoids under development ...
Miles, DDS MD, Professor and Chair Otolaryngology Head and Neck Surgery Lenox Hill Hospital New York, and senior author, commented, “Novel technologies that have potential to improve our ability to determine surgical margins are needed in order to improve outcomes in head and neck cancer. This work represents a novel optical coherence imaging approach which has shown ...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
Eikonoklastes is also advancing a new generation of tissue factor (TF) therapies (ET-201) for the treatment of Triple Negative Breast Cancer and other oncology indications. About Forge Biologics Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. ...
Perimeter is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs. ...
Developed by specialists from the medical, technology, and design fields, the platform aims to establish a culture of preventative healthcare in Latvia as well as educate women on breast cancer risks and contraception methods. By educating more individuals and collecting real-world data, skrinings.lv is actively contributing to decreasing unwanted pregnancies, ...